Esperion Therapeutics Inc (ESPR) Stock Analysis

Sector: HEALTHCARE - DRUG MANUFACTURERS - SPECIALTY & GENERIC

Exchange: NASDAQ

Key Metrics

• Price: $3.36
• Market Cap: $796.08M
• EPS: $-0.54
• 52-Week High: $4.17
• 52-Week Low: $0.69

Market Sentiment

Esperion Therapeutics Inc currently has a Neutral sentiment score of 0.12.

About Esperion Therapeutics Inc

Esperion Therapeutics, Inc. is a biopharmaceutical company focused on delivering innovative therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). Headquartered in Ann Arbor, Michigan, Esperion is committed to transforming the treatment landscape for cardiovascular disease by developing and commercializing novel lipid-lowering agents. With a robust pipeline and a strong emphasis on patient-centered solutions, the company is well-positioned to play a significant role...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Esperion Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does ESPR pay dividends?

Esperion Therapeutics Inc (ESPR) does not currently pay a regular dividend.

What is ESPR's market cap?

Esperion Therapeutics Inc (ESPR) has a market capitalization of $796.08M with a current stock price of $3.36.